Lars Mouritsen is the Founder and CEO of Avendium, where he brings over 25 years of experience in quality assurance, regulatory affairs, laboratory operations, and clinical development across the pharmaceutical, biotechnology, and diagnostics industries. A certified Diplomate in Laboratory Management (ASCP), Lars has led global GxP vendor qualification programs, directed regulatory strategies for oncology clinical trials, and built quality systems aligned with CAP, CLIA, ISO standards, and FDA 510(k) submissions.

Prior to founding Avendium, Lars held leadership roles at Sumitomo Pharma Oncology, Tolero Pharmaceuticals, and Sorenson Genomics, where he oversaw cross-functional programs in biomarker development, companion diagnostics, and laboratory innovation. He is recognized for his strategic, risk-based approach to compliance and his ability to design scalable systems that meet both regulatory requirements and business goals.

Lars holds a Bachelor of Science in Biology from the University of Utah and maintains certifications in immunology, molecular biology, quality systems, and Six Sigma. His leadership drives Avendium’s mission to provide pragmatic, expert-driven quality and regulatory solutions that enable life science companies to grow with confidence.

Regan supports branding, outreach, and internal operations. A licensed Registered Nurse with a Bachelor of Science in Nursing, Regan brings clinical insight, a passion for science, and a keen eye for strategic communication. She plays a vital role in ensuring Avendium’s messaging, marketing, and internal workflows reflect the firm’s commitment to excellence. Regan is known for her adaptability and dedication to supporting the team wherever needed to advance client outcomes and company growth.

Ray is a senior executive with over 25 years of experience leading regulatory, quality, and operational functions across the medical device, pharmaceutical, biologics, transplant, and clinical sectors. He specializes in global regulatory strategy, continuous improvement, and patient safety initiatives. Ray has successfully led interactions with regulatory authorities across the U.S., EU, PMDA, SFDA, and other international markets. His leadership is defined by strategic vision, cross-functional collaboration, and a commitment to driving compliant and scalable quality systems that align with business and regulatory goals. 

Neil is a seasoned QA leader with over 26 years of experience in the pharmaceutical, CRO, and clinical software industries. He has held senior roles including Director and VP of Quality, leading global quality initiatives and regulatory compliance efforts. Neil has implemented end-to-end Quality Management Systems, prepared companies for regulatory inspections, and conducted mock audits for GxP environments. He has presented at DIA conferences, contributed to industry guidance on data integrity, and trained international regulatory authorities. His expertise spans validation, regulatory strategy, inspection readiness, and cross-functional quality leadership across complex, fast-paced organizations. 

Breeann is a quality and operations leader with experience across biotechnology, nutraceuticals, and pharmaceuticals. She began her career in a high-throughput DNA testing lab and advanced to laboratory manager and safety officer. A Lean Six Sigma Black Belt, she specializes in root cause analysis, KPI monitoring, and continuous improvement in regulated environments (ISO 17025, CAP/CLIA, AABB, NYSDOH). Breeann supports companies in building and implementing Quality Management Systems aligned with ISO 9001 and ISO 13485, guiding them through certification readiness and successful audits with notified and certifying bodies.

Tim Dore is a drug discovery specialist with expertise in strategy and project management, molecular design, chemical library design, hit finding through virtual and biological screening, and hit through lead optimization. He is deeply experienced leading international, multidisciplinary research teams to conduct cutting-edge research in medicinal chemistry and chemical biology. He has a proven track record in conceiving, launching, and building new initiatives and driving drug discovery. He has worked with multiple therapeutic modalities and disease areas and created the chemistry to drive the discovery platforms at several biotech start-up companies. Prior to working in the biotechnology and pharmaceutical industry, Dr. Dore was on the faculty at the University of Georgia and New York University Abu Dhabi and a visiting professor at Kyoto University. He holds a BS in chemistry from the University of North Carolina-Chapel Hill and a PhD in chemistry from Stanford University. He completed postdoctoral training with Nobel Laureate Roger Y. Tsien at the Howard Hughes Medical Institute and the University of California, San Diego.